Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.39 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13442980 | 1.00 | NR1H2 (0.44) | NR1H2CHRM1GPR119MEN1ALDH1A1 | |
| SCHEMBL17477191 | 1.00 | NR1H2 (0.44) | NR1H2CHRM1GPR119MEN1ALDH1A1 | |
| SCHEMBL15217058 | 0.88 | SETD7 (0.42) | NR1H2GPR119MEN1ALDH1A1MAPT | |
| SCHEMBL28722434 | 0.88 | SETD7 (0.42) | NR1H2GPR119MEN1ALDH1A1MAPT | |
| SCHEMBL28722436 | 0.88 | SETD7 (0.42) | NR1H2GPR119MEN1ALDH1A1MAPT | |
| SCHEMBL3109070 | 0.85 | SETD7 (0.41) | NR1H2GPR119MEN1ALDH1A1MAPT | |
| SCHEMBL3106223 | 0.85 | SETD7 (0.41) | NR1H2GPR119MEN1ALDH1A1MAPT | |
| SCHEMBL23235715 | 0.85 | SLC6A9 (0.44) | NR1H2GPR119MEN1ALDH1A1MAPT | |
| SCHEMBL22346776 | 0.85 | NR1H2 (0.46) | NR1H2GPR119MEN1ALDH1A1MAPT | |
| SCHEMBL3316577 | 0.85 | NR1H2 (0.46) | NR1H2GPR119MEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| EP-3640248-B1 | AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2022-06-07 | — | — | US | disclosed |
| US-20200087296-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2020-03-19 | — | — | US | disclosed |
| WO-2016015605-A1 | COMPOUNDS AS CDK SMALL-MOLECULE INHIBITORS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087296-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, EGFR | NR1H2 3528/4885CHRM1 4866/4885GPR119 2011/4885 |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | WEE1, WEE2, EGFR | NR1H2 3528/4885CHRM1 4866/4885GPR119 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.